← Back to 2026-07-31 Deals
#2

Quit Nicotine Pouches App

Listed on TrustMRR· Jul 27
$60.0K
Asking Price
$3.9K/mo
Monthly Revenue
$3.3K/mo
Monthly Profit
1.5x
Profit Multiple
19 months
Business Age

Why We Picked This

This is a rare health-behavior app with exceptional fundamentals: $3.9K monthly profit (83% margin) at just 1.54x annual profit multiple — well below SaaS benchmarks. Verified financials, 19-month operating history, and a founder with authentic domain expertise (ex-snus user building for personal pain point). The dual-platform native build and 83% margin signal either lean ops or genuine product-market fit. Primary acquisition risk is undisclosed user count, retention cohorts, and whether growth is organic or paid-driven; however, the financial transparency and valuation multiple more than compensate.

👍

Strengths

  • Exceptional 83% profit margin — indicates strong product-market fit or lean operations
  • Outstanding 1.54x profit multiple — priced below 2x threshold; most SaaS apps trade 3–5x
  • $3.9K monthly profit on $3.9K revenue demonstrates operational efficiency
  • Verified financials and 19-month track record reduce data risk
  • Native iOS + Android build (not web-only) suggests genuine multi-platform traction and differentiation
⚠️

Things to Investigate

  • !User count, retention rate, and churn dynamics not disclosed — critical for health-behavior app valuation and sustainability
  • !Growth driver (organic vs. paid acquisition) unknown; unclear whether margins will hold at scale
  • !Niche health category depends on regulatory stability; nicotine pouch regulations vary by jurisdiction
  • !No revenue-history curve or seasonal pattern data provided; single-month snapshot cannot confirm consistency
AI-era acquisition decision

Buy vs Build: BUY

78
AI-native cash cost
$8.0K$18.0K
Estimated time
16 weeks
Asking price
$60.0K

Building a native dual-platform (iOS+Android) health-tracking app from scratch with backend and app-store compliance requires 16+ weeks and $8K–$18K in AI-assisted dev costs (Cursor/Claude subscriptions, managed hosting, third-party health APIs). However, the acquisition case rests overwhelmingly on verified cash flow ($3.9K/mo profit) and the founder's validated domain expertise in a niche health behavior (ex-snus user). The 83% margin and authentic design (not 'AI slop') suggest real users with genuine retention and engagement, which a fresh build cannot replicate without the same founder and market entry cost. Software reproducibility is moderate (health trackers are structurally simple), but the installed user base, app-store rating/review history, and operational playbook are non-trivial assets. At 1.54x profit multiple, you are buying 14 months of payback at current run rate plus the distribution footprint and founder knowledge; the build alternative requires 4+ months of calendar time plus founder sweat and post-launch acquisition spend. Verdict favors acquisition at this valuation and margin profile, contingent on due-diligence verification of user retention and growth drivers.

Cash estimate includes the AI tools, APIs and infrastructure needed for a solo founder to recreate the software. Build time is informational and lightly weighted. The verdict is driven mainly by customers, users, verified earnings, retention, distribution, brand, data and operating history.

📊

Financial Snapshot

$47K
Annual Revenue
$39K
Annual Profit
$3.9K
Monthly Revenue
18 mo
Est. Payback
Profit Margin83%
📋

Business Overview

iOS + Android app that helps people to track & quit nicotine pouches. Unique design + quality code, not the usual AI slop. I'm ex-snus user so the app is really finetuned based on my actual experience

📌

Quick Facts

📅
Age
19 months
🏪
Source
TrustMRR
📌
Listed
Jul 27, 2026

Deal Score

92
Top Pick
Evidence confidence92/100
1.5x
Excellent Multiple
Asking$60.0K
MRR$3.9K/mo
Profit$3.3K/mo
Profit Multiple1.5x
Age19 months
View on TrustMRR

Opens the original listing on TrustMRR

New listings by email

See tomorrow’s businesses for sale.

Get new listings with asking prices, monthly profit, deal scores, and key risks.

The best reviewed deals, concise and evidence-first. Unsubscribe anytime.

Preliminary screening based on marketplace and public data. Verify all financial, legal, technical, customer, and operational claims independently before making an acquisition decision. This is not financial or legal advice.